433 related articles for article (PubMed ID: 34721403)
1. Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy.
Teisseyre M; Cremoni M; Boyer-Suavet S; Crepin T; Benzaken S; Zorzi K; Esnault V; Brglez V; Seitz-Polski B
Front Immunol; 2021; 12():738788. PubMed ID: 34721403
[TBL] [Abstract][Full Text] [Related]
2. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
[TBL] [Abstract][Full Text] [Related]
3. Primary Membranous Nephropathy.
Couser WG
Clin J Am Soc Nephrol; 2017 Jun; 12(6):983-997. PubMed ID: 28550082
[TBL] [Abstract][Full Text] [Related]
4. Multi-Autoantibody Signature and Clinical Outcome in Membranous Nephropathy.
Ghiggeri GM; Seitz-Polski B; Justino J; Zaghrini C; Payré C; Brglez V; Dolla G; Sinico A; Scolari F; Vaglio A; Prunotto M; Candiano G; Radice A; Bruschi M; Lambeau G;
Clin J Am Soc Nephrol; 2020 Dec; 15(12):1762-1776. PubMed ID: 33257410
[TBL] [Abstract][Full Text] [Related]
5. Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy.
Seitz-Polski B; Debiec H; Rousseau A; Dahan K; Zaghrini C; Payré C; Esnault VLM; Lambeau G; Ronco P
J Am Soc Nephrol; 2018 Feb; 29(2):401-408. PubMed ID: 29114041
[TBL] [Abstract][Full Text] [Related]
6. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.
van de Logt AE; Dahan K; Rousseau A; van der Molen R; Debiec H; Ronco P; Wetzels J
Kidney Int; 2018 Apr; 93(4):1016-1017. PubMed ID: 29571438
[No Abstract] [Full Text] [Related]
7. Fibrinogen-albumin ratio predicts treatment response in phospholipase A2 receptor-associated membranous nephropathy with nephrotic syndrome.
Duan S; Chen S; Chen C; Lu F; Pan Y; Lu Y; Li Q; Liu S; Zhang B; Mao H; Xing C; Yuan Y
Ren Fail; 2024 Dec; 46(1):2359024. PubMed ID: 38832491
[TBL] [Abstract][Full Text] [Related]
8. Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy.
Teisseyre M; Cremoni M; Boyer-Suavet S; Ruetsch C; Graça D; Esnault VLM; Brglez V; Seitz-Polski B
Front Immunol; 2022; 13():859419. PubMed ID: 35603210
[TBL] [Abstract][Full Text] [Related]
9. Primary membranous nephropathy in adolescence: A prospective study.
Kumar V; Varma AK; Nada R; Ghosh R; Suri D; Gupta A; Kumar V; Rathi M; Kohli H; Jha V; Gupta K; Ramachandran R
Nephrology (Carlton); 2017 Sep; 22(9):678-683. PubMed ID: 27334445
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy: A retrospective study.
Zhou K; Zhou J; Zhou L; Xue J; Liu B; Zhang Z; Zhang X; Cai T; Shao S; Huang B; Zhang Y; Hu Z; Wang L; Liu X
PLoS One; 2024; 19(5):e0302100. PubMed ID: 38718066
[TBL] [Abstract][Full Text] [Related]
11. Antibodies against M-Type Phospholipase A2 Receptor May Predict Treatment Response and Outcome in Membranous Nephropathy.
Qu Z; Zhang MF; Cui Z; Wang J; Wang M; Zhang YM; Wang F; Wang X; Meng LQ; Cheng XY; Liu G; Zhao MH
Am J Nephrol; 2018; 48(6):438-446. PubMed ID: 30472708
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of
Guo Y; Guo N; Wang J; Wang R; Tang L
Ren Fail; 2021 Dec; 43(1):729-736. PubMed ID: 33904354
[TBL] [Abstract][Full Text] [Related]
13. High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy.
Seitz-Polski B; Dahan K; Debiec H; Rousseau A; Andreani M; Zaghrini C; Ticchioni M; Rosenthal A; Benzaken S; Bernard G; Lambeau G; Ronco P; Esnault VLM
Clin J Am Soc Nephrol; 2019 Aug; 14(8):1173-1182. PubMed ID: 31340979
[TBL] [Abstract][Full Text] [Related]
14. [Membranous nephropathy: Pathophysiology and natural history].
Seitz-Polski B; Lambeau G; Esnault V
Nephrol Ther; 2017 Apr; 13 Suppl 1():S75-S81. PubMed ID: 28577747
[TBL] [Abstract][Full Text] [Related]
15. Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy.
Zaghrini C; Seitz-Polski B; Justino J; Dolla G; Payré C; Jourde-Chiche N; Van de Logt AE; Booth C; Rigby E; Lonnbro-Widgren J; Nystrom J; Mariat C; Cui Z; Wetzels JFM; Ghiggeri G; Beck LH; Ronco P; Debiec H; Lambeau G
Kidney Int; 2019 Mar; 95(3):666-679. PubMed ID: 30784662
[TBL] [Abstract][Full Text] [Related]
16. [Update membranous nephropathy].
Hoxha E; Huber TB
Dtsch Med Wochenschr; 2020 Oct; 145(20):1481-1485. PubMed ID: 33022730
[TBL] [Abstract][Full Text] [Related]
17. [Membranous nephropathy: New insights in therapeutic approach].
Dahan K
Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
[TBL] [Abstract][Full Text] [Related]
18. Management of Membranous Nephropathy after MENTOR.
Trivin-Avillach C; Beck LH
Clin J Am Soc Nephrol; 2020 Mar; 15(3):415-417. PubMed ID: 31740571
[No Abstract] [Full Text] [Related]
19. Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy.
Stefan G; Stancu S; Zugravu A; Popa O; Zubidat D; Petre N; Mircescu G
Ren Fail; 2022 Dec; 44(1):258-268. PubMed ID: 35172682
[TBL] [Abstract][Full Text] [Related]
20. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
